|
|
|
|
|
|
|
|
||
![]() |
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
||||
|
Quote:
Duke, Good catch. As you know I have been following G-Protein Response Modifiers for rosacea for nearly 7 years and have been involved in preliminary G-Protein testing for vascular hyper-responsiveness, uncontrolled vascular growth and vasculopathy. G-Proteins are one of the backbone treatment fields for Physiologists. They are also the key to rosacea remission... not a cure... but remission. You can't block the hundreds of dilators and inflammatory substances in the skin, but you can block one specific "G-Protein Subunit" from binding onto hundreds of receptors and effectively blocking the entire signal transduction cascade from ever occuring. This means that if a dilator substance (a key) binds onto a receptor (a lock), a g-protein must couple to the "key" and "lock" to allow further action. If the g-protein cannot couple with these two, then nothing happens.... the cells are never told to dilate OR inflammatory cells are never told to be produced OR DNA is never told to be replicated into damaging enzymes, etc. This is selective targetting without side effect. There is now a G-Protein response modifier available oversees that blocks neutrophil mediated inflammation (they are using it just for cosmetics and anti-aging) but it is much more than this as rosacea is a neutrophil-based disorder. We can use this product right now and I would predict that it would be the most effective anti-rosacea topical to date, bar none. Plus, this same company is developing specific rosacea treatments. This is the way to go and the best way to attack rosacea. Block one G-protein to block one hundred inflammatory pathways. It's what they call "smart" medicine. I am completing an interview with several companies currently researching and developing oral and topical g-protein inhibitor drugs for inflammatory dermatoses and rosacea... let me complete my interviews and put a report together as this important subject deserves more than a posting.
__________________
_ Best, Geoffrey Dr. Geoffrey Nase Ph.D: Neuro-Vascular Physiologist Email: drnase1000@hotmail.com Bibliography: http://drnase.com All posts are for informational purposes only. Please visit our Home Page to view our Medical Disclaimer. |
|
|||
|
Quote:
|
|
||||
|
Hi Dan, I am following up on both G-protein products. It looks like US researchers and doctors will be able to get samples from the UK and Japan. Signum Biosciences is developing a new product based on G-protein Response Modulation. Their first product, for anti-aging, called Arazine will be available in two to four months and they are currently working on a second generation of products to target inflammatory skin disorders such as rosacea, psoriasis and eczema. What they don't realize yet is that Arazine is an excellent treatment choice for rosacea due to its anti-inflammatory actions in the skin and its affect on damaging neutrophils. It is more than an anti-aging product. We can use this right now! Information from their Website - Soon to be followed up with indepth interviews on their current product and their second generation rosacea product: According to Signum Bioscience’s Development Pipeline, SIG990 is in the preclinical phase as a rosacea treatment. G-protein Response Modulators Signum Bioscience’s patented compounds and methods revolve around a group of derivatives called prenyl peptides. Signum’s GPM Technology Platform constitutes a new class of non-steroidal anti-inflammatories that have broad utility over multiple therapeutic areas by acting as G-protein modulators (GPMs). Initially anti-aging and anti-inflammatory compounds will have immediate impact in skin care products as topical cosmeceuticals (e.g. Arazine™) followed by pharmaceutical inflammatory skin applications. Furthermore, Signum’s goal is the development of anti-inflammatory pharmaceuticals. GPM Pharmaceutical Development The most common topical treatment options include antimicrobial agents (e.g. Metrogel, Clindamycin, Clindamycin-Benzoyl peroxide, Sodium Sulfacetamide/Sulfur and Finacea) which inhibit ROS generation by neutrophils, thereby reducing inflammation. However, these treatments do not reduce the initiating inflammatory events (inflammatory mediator release and neutrophil recruitment) of rosacea. Conversely, GPMs inhibit inflammation directly and indirectly by reducing activity and/or expression of all the key players in rosacea, not just ROS production Results demonstrate that GPMs: •Inhibit release of key inflammatory mediators (e.g. TNF-α, IL-6, IL-8, VCAM-1, GM-CSF, Gro-α, MCP-1) •Inhibit neutrophil adhesion and infiltration •Inhibit ROS production from neutrophils Given Arazine’s safety and effectiveness as an anti-inflammatory, second generation GPM compounds, provide an effective nonsteroidal alternative for patients suffering from skin diseases such as: rosacea, acne, psoriasis and eczema. The first GPM based topical containing Arazine is planned to be released to the Japanese market in the second quarter of 2010.
__________________
_ Best, Geoffrey Dr. Geoffrey Nase Ph.D: Neuro-Vascular Physiologist Email: drnase1000@hotmail.com Bibliography: http://drnase.com All posts are for informational purposes only. Please visit our Home Page to view our Medical Disclaimer. |
|
|||
|
Thanks for the info Dr. Nase. What is the relationship between Cyclic AMP and G Protein? This product: About Strata-C | goodbye-redness.com seems to target inflammation similar to what you are talking about.
|
|
||||
|
Quote:
Their website statements are incorrect. Cyclic AMP is found inside cells and activates calcium channels... it does nothing topically; however, with that said, the overall formulation seems to be quite good. I know LadyGolf really likes Stata G... give her a holler.
__________________
_ Best, Geoffrey Dr. Geoffrey Nase Ph.D: Neuro-Vascular Physiologist Email: drnase1000@hotmail.com Bibliography: http://drnase.com All posts are for informational purposes only. Please visit our Home Page to view our Medical Disclaimer. |
|
||||
|
Doug, Preclinical refers to studies done in the laboratory or on humans (in isolated cases). They are anecdotal with no proven clinical application yet. Thus the next stage is the clinical stage where studies are performed on large numbers of human test subjects to determine if the treatment is valid and has a real effect. Michael |
![]() |
| Thread Tools | |
| Display Modes | |
|
|